Recombinant Vaccines for Prevention of AIDS and Other Diseases

有许多疾病没有疫苗，而另一些疾病的疫苗不是最佳的或有明显的副作用。 该项目的目标是开发新的载体，表征病毒抗原，确定体液和细胞介导免疫的靶点，并利用这些信息开发候选疫苗。重组病毒活疫苗、DNA疫苗和重组蛋白疫苗正在开发中。目前，我们正在研制以牛痘病毒为载体的艾滋病毒疫苗。这些疫苗首先在小动物身上进行测试，然后在非人类灵长类动物身上进行测试。我们实验室开发的MVA载体疫苗的1期和2期临床试验正在由合作者进行。该疫苗是安全和免疫原性。动物研究揭示了用gp140和三聚体gp120蛋白以及用病毒样颗粒对MVA引发的免疫的良好加强。

There are many diseases for which there are no vaccines and others for which the vaccines are not optimal or have significant side effects. The objectives of this project are to develop new vectors, characterize viral antigens, determine targets of humoral and cell mediated immunity, and use this information to develop candidate vaccines. Live recombinant viral vaccines, DNA vaccines and recombinant protein vaccines are being developed. Presently we are working on vaccinia virus-vectored vaccines for HIV. The vaccines are first tested in small animals and then in non-human primates. Phase 1 and 2 clinical trials with MVA-vectored vaccines developed in our laboratory are ongoing by collaborators. The vaccines were safe and immunogenic. Animal studies revealed good boosting of MVA primed immunizations with gp140 and trimeric gp120 proteins and with virus-like particles.